Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

BeOne Medicines

Tracked across 9 events · 102 articles · First seen Apr 13, 2026 · Last active Sep 04, 2026

Sentiment
31
Attention
8
Events
9
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 50
Business
Impact: BeOne Medicines received the 'Outstanding Global Oncology Company of the Year' award, recognizing its advancements in R&D and manufacturing of cancer therapies, which positively impacts its reputation and market standing.
May 11, 2026 · 6 articles
6 90
Tech
Impact: BeOne Medicines announced positive topline results from its Phase 3 MANGROVE study for Zanubrutinib, which is expected to significantly boost its market position and future revenue in oncology.
Jun 30, 2026 · 6 articles
4 60
Business
Impact: BeOne gains exclusive rights to develop and commercialize Revolution Medicines' RAS(ON) inhibitors in select Asian markets, strengthening its oncology portfolio and regional presence. It will also fund a Phase 3 study, leveraging its development capabilities.
Aug 10, 2026 · 7 articles
6 50
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: BeOne Medicines agreed to provide an oncology medicine at reduced United States — Medicaid pricing and committed to $11 billion U.S. investment through 2029. It also announced a $300 million onshoring investment in New Jersey, enhancing its U.S. manufacturing footprint.
Aug 18, 2026 · 37 articles
0 0
Business
Impact: BeOne Medicines is a partner of Zymeworks with exclusive rights to develop and commercialize zanidatamab in certain territories. The conference participation does not directly affect BeOne Medicines.
Aug 11, 2026 · 6 articles
4 30
Tech
Impact: BeOne Medicines provided Tislelizumab under a clinical drug supply agreement for AnBogen Therapeutics's Phase 1/2 clinical trial.
Apr 13, 2026 · 6 articles
2 0
Business
Impact: Dr. Michelle Mellion previously held a Chief Medical Officer role at BeOne Medicines, leading clinical development efforts.
May 12, 2026 · 6 articles
1 0
Business
Impact: BeOne Medicines is a partner with exclusive rights to develop and commercialize zanidatamab in certain territories; mentioned in the company description but not directly involved in this event.
Jul 16, 2026 · 6 articles
8 0
Business
Jun 07, 2026 · 22 articles
United States ↔ BeOne Medicines
United States ↔ BeOne Medicines
ERGEN INTELLIGENCE
Track BeOne Medicines live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.